Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
When the Price of (INO) Talks, People Listen | news.google.com • |
Inovio Pharmaceuticals (NASDAQ:INO) Price Target Lowered to $7.00 at Royal Bank of Canada | news.google.com • |
INOVIO Reports Inducement Grants Under Inducement Plan | news.google.com • |
INOVIO Reports Inducement Grants Under Inducement Plan | prnewswire.com • |
INOVIO Reports Inducement Grants Under Inducement Plan | news.google.com • |
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-14 | 2024-09 | -1.2 | N/A | N/A | N/A |
2024-08-08 | 2024-06 | -1.15 | -1.19 | -0.04 | -3.48% |
2024-05-13 | 2024-03 | -1.08 | -1.31 | -0.23 | -21.30% |
2024-03-06 | 2023-12 | -1.58 | N/A | N/A | N/A |
2023-11-09 | 2023-09 | -1.56 | -1.08 | 0.48 | 30.77% |
2023-08-09 | 2023-06 | -1.68 | -1.56 | 0.12 | 7.14% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-05-10 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
2023-03-01 | RBC Capital | Upgrade | Sector Perform | |
2022-11-08 | Maxim Group | Downgrade | Buy | Hold |
2022-10-31 | B of A Securities | Downgrade | Neutral | Underperform |
2022-08-09 | RBC Capital | Upgrade | Sector Perform | |
2022-05-10 | Oppenheimer | Downgrade | Outperform | Perform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-05-14 | BENITO SIMON X | Director | 10.02K | Conversion of Exercise of derivative security |
2024-05-14 | DANSEY ROGER D | Director | 6.75K | Conversion of Exercise of derivative security |
2024-05-14 | HUMEAU LAURENT M | Officer | 24.34K | Conversion of Exercise of derivative security |
2024-05-14 | KIES PETER D | Chief Financial Officer | 24.74K | Conversion of Exercise of derivative security |
2024-05-14 | MILLER ANN CALBY M.D. | Director | 7.71K | Conversion of Exercise of derivative security |
2024-05-14 | SHEPARD JAY P. | Director | 7.04K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 20.07M | 8.96M | 7.49% |
2023-06-29 | Shaw D.E. & Co., Inc. | 7.60M | 3.39M | 2.84% |
2023-06-29 | Blackrock Inc. | 6.09M | 2.72M | 2.27% |
2023-06-29 | Renaissance Technologies, LLC | 5.44M | 2.43M | 2.03% |
2023-06-29 | Millennium Management Llc | 5.34M | 2.38M | 1.99% |
2023-06-29 | Jane Street Group, LLC | 3.20M | 1.43M | 1.19% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 8.26M | 3.69M | 3.08% |
2023-06-29 | Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 4.06M | 1.81M | 1.51% |
2023-06-29 | Vanguard Extended Market Index Fund | 3.35M | 1.50M | 1.25% |
2023-06-29 | Vanguard Strategic Equity Fund | 3.00M | 1.34M | 1.12% |
2023-08-30 | iShares NASDAQ Biotechnology ETF | 1.88M | 844.39K | 0.70% |
2023-05-30 | Fidelity Extended Market Index Fund | 1.27M | 761.76K | 0.47% |
Dividend | Date |
---|---|
0.0057 | 2017-09-28 |
0.0057 | 2017-08-29 |
0.0057 | 2017-07-27 |
0.0057 | 2017-06-28 |
Split | Date |
---|---|
1 : 12 | 2024-01-25 |
1 : 4 | 2014-06-06 |
1 : 4 | 2014-06-05 |
0.25 : 1 | 2004-09-13 |
-
From 3/7 PR:... NIAID to Start Testing Inovio Coronavirus in a Month (says Fauci...)
https://www.google.com/amp/s/www.coinspeaker.com/inovio-stock-ino-trials-vaccine/amp/
Director of the United States National Institute of Allergy and Infectious Diseases (NIAID), Dr. Anthony Fauci, said on Tuesday that yesterday NIAID authorized entrance of the vaccine against the COVID-19 in phase one.
He said that “very soon, in a month, month and a half, we’ll be sticking the first person in the arm with the vaccine. But this is only the first stage. We will be giving it to normal healthy people. Phase two trial comes in the next three or four months. The whole process will take one, one and a half years at least.”
-
My thoughts on what may be driving the stock higher right now:
-
April is approaching. $INO human trials of INO-4800 are expected to commence. PR probably coming soon. ($MRNA continues to get lift around trial updates)
-
3/26 PR on $INO VGX-3100 positive Phase Ii results.
-
3/24 PR on $11.9 Million DOD contract landed by Ology Bioservices, a contract development and manufacturing organization, to work with $INO on the manufacturing of its potential Covid-19 vaccine.
Anything else?
-
-
One thing is certain - these times are like no other times. $2 trillion in economic stimulus. Loosened FDA guidelines around everything Covid-19. Public and private sector partnerships (Bill Gates, Elon Musk...) to accelerate speed to market for vaccines, rapid test kits, ventilators, PPE...
Like many I look forward to $INO commencing human trials with INO-4800 next month. Maybe it will fail. Maybe it won’t.
These times call for unprecedented measures and a bit more hope and optimism on what might be possible with perhaps a little less emphasis on what was or may have been as the past is not offering a lot of guidance on what our future has in store for us.
-
One thing is for sure... there are plenty of unknowns and market tension between $INO buyers and sellers to make for an exciting market and trading opportunities.
Do your research.
Draw your own conclusions.
Read this board and others like it purely for their entertainment value. You may get lucky and find a handful of people that are posting information that you find valuable. The rest is just noise...
Stay sane and stay healthy. GLTA.
-
To anyone who believes $INO executives committed fraud...
To anyone who is a fan of Citron...
To anyone who has ever engaged a bottom fishing attorney to join a purported class action lawsuit against a company...
If you fit the build, then do yourself a favor and refrain from reading $INO press releases.
You will not like what you read...the doom and gloom is just not there. $INO scientists are executing. $INO clinical trials are moving forward.
Do yourself a favor and put your energies into finding the next company that Citron attemp to trash.
-
Dr. J. Joseph Kim, Inovio's President & CEO, shared this accelerated timeline at the U.S. Coronavirus Task Force meeting at the White House on March 2. Dr. Kim said, "Inovio is the leader in coronavirus vaccine development and the only company with a Phase 2 vaccine for a related coronavirus that causes Middle East Respiratory Syndrome (MERS). Using our modern DNA medicines platform, we designed our DNA vaccine INO-4800 in three hours after the publication of the genetic sequence of the novel coronavirus that causes COVID-19."
Dr. Kim continued, "We immediately began preclinical testing and small-scale manufacture and have already shared robust preclinical data with our public and private partners. We plan to begin human clinical trials in the U.S. in April and soon thereafter in China and South Korea, where the outbreak is impacting the most people. We plan on delivering one million doses by year end with existing resources and capacity. However, we will need additional resources to scale up to make enough doses to help protect Americans from COVID-19 as well as to lead global efforts to curtail this virus."
-
Today’s news... $INO proxy statement filed with the SEC. Link below.
The team at $INO is executing.
103.6% attainment against their goals.
https://www.sec.gov/Archives/edgar/data/1055726/000105572620000022/ino-2020xproxy.htm
Read and invest with a winning team.
-
Someone asked...
Yes, $INO is going straight to human trials with INO-4800, their Covid-19 vaccine candidate.
** human trials start in April **
Please read and feel good about your investment.
-
Please read, then buy and hold or flip on the way up...
Say goodbye to Citron.
Say goodbye to threats of class action lawsuits.
Say hello to their INO-4800 trial (Covid-19) which we will likely hear about soon - next week?
This company is doing great things.
-
Here is the most recent news as of 3/26 (yesterday).
I believe this news is the likely catalyst for today’s run. $INO is far greater than INO-4800, it’s Covid-19 vaccine candidate.
Please read and appreciate all of the great work underway at $INO. While I would like to see this company better capitalized, they are executing far better than most in their space.
-
The fear, doubt and uncertainty that Citron injected into $INO shareholders along with the POS ambulance chasing attorneys pleading with us to join their purported class action lawsuits against $INO look pretty silly now.
$INO continues to execute, and their Phase 2 results released just yesterday (3/26) highlight that this company is not fraudulent, that it has a robust pipeline, and that it is having success with a number of drug candidates developed with its DNA vaccine platform, the same platform used to develop its Covid-19 vaccine (INO-4800) in 3 hours after The Covid-19 sequencing was available to the public.
We should hear more soon on the INO-4800 trial. GLTA. Goodbye to Citron.
-
-
$INO The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmac... https://finance.yahoo.com/news/zacks-analyst-blog-highlights-gilead-141602648.html?soc_src=social-sh&soc_trk=tw via @YahooFinance
-
-
-
-
This company was just awarded by the defense department. I don’t see tanks in there future I see rockets.
-
-
When the Price of (INO) Talks, People Listen
news.google.com • -
INOVIO Reports Inducement Grants Under Inducement Plan
news.google.com • -
INOVIO Reports Inducement Grants Under Inducement Plan
prnewswire.com • -
INOVIO Reports Inducement Grants Under Inducement Plan
news.google.com • -
INOVIO to Present at Upcoming Scientific Conferences
news.google.com • -
INOVIO to Present at Upcoming Scientific Conferences
prnewswire.com • -
INOVIO to Present at Upcoming Scientific Conferences
news.google.com • -
INOVIO to Present at Upcoming Scientific Conference
prnewswire.com • -
Inovio Pharmaceuticals, Inc. (INO) Q2 2024 Earnings Call Transcript
seekingalpha.com • -
INOVIO Reports Inducement Grant Under Inducement Plan
prnewswire.com • -
INOVIO Reports Inducement Grant Under Inducement Plan
prnewswire.com • -
INOVIO Added to Russell 2000® Index Effective July 1, 2024
prnewswire.com • -
INOVIO Reports Inducement Grants Under Inducement Plan
prnewswire.com •